91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
In this article from Drug Development & Delivery, Suzanne Jansen, Head of QC Laboratory, discusses the importance of faster data turnaround within the analytical lab to facilitate adaptive dosing decisions that will benefit all stages of clinical trials.
-
In this article from International Biopharmaceutical Industry, Harpreet Gill, Vice President of Real-World Solutions - Project Management reflects on how investigators and sites can be supported and partnered as the use of decentralised clinical trials evolves.
-
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
This news article, from Applied Clinical Trials, outlines findings from 91黑料’s recent survey of over 100 industry professionals on their opinions on future research within the therapeutic area of obesity treatment.
-
This news piece from The Clinical Trial Vanguard provides an overview of the findings from 91黑料’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
-
In this article in The Journal of mHealth, Madelaine MacKay, Senior Director, Product Management outlines that to keep patients and care provider needs at the core, four elements should be considered when adopting modern clinical trial approaches: flexibility, consistency, creativity, simplicity.
-
This article from Clinical Insider outlines 91黑料’s view that the demand for clinical trial services will increase in 2024, in addition to providing an overview of the results of the recent 91黑料 biotech sector survey, the findings of which suggest that biotech R&D spending is likely to increase.
-
In this article, 91黑料’s Andreas Dreps and Martin Lachs discuss how the success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
-
In this article in Clinical Research News, Alyssa Gilliam, Vice President, CSM & IRT and Chad Crafford, Clinical Supplies Manager outline practical considerations for managing your CGT supply chain to minimise risk, mitigate cost and complexity.
-
This article from Fierce Biotech provides an overview of findings from the 91黑料 2023 biotech sector survey, which shows that despite cash struggles, 60% of the survey respondents anticipate their R&D spend to rise over the next one to two years.
